Stock Ratings / Health Care / CDIO / dividends

TRIB (56) QCLS (42) BMRA (39) VRAX (58) ⌘ Pro Terminal →

Cardio Diagnostics Holdings Inc. (CDIO) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.75 +2.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cardio Diagnostics Holdings Inc. (CDIO) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CDIO)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CDIO)

✓Walkthrough of CDIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CDIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.23%▼ DESCENDING CHANNEL

2026-10-30O $1.72H $1.75L $1.67C $1.75VOL 12.0K

RES: $2.17SUP: $1.48SMA50: $1.87SMA200: $2.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CDIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CDIO Butterfly Map → + Track CDIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -57.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CDIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CDIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CDIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CDIO)

Health Care Rank #937 of 1016 ⚔️ TRIB vs CDIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CDIO vs. TRIB, QCLS, BMRA, VRAX)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardio Diagnostics Holdings Inc. (CDIO) ranks #937 by composite RQD confidence (31/100, grade E) and #943 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, CDIO leads on earnings valuation at N/A trailing P/E, while CDIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VRAX currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CDIO at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CDIO ACTIVE Cardio Diagnostics Holdings Inc.	E	31/100	—	—	-35.0%	+2.94%	$5.2M	Benchmark Subject
TRIB Trinity Biotech plc	D+	56/100	—	—	—	-2.50%	$5.4M	/trib-vs-cdio →
QCLS Q/C Technologies Inc.	D-	42/100	—	—	-35.0%	-3.44%	$3.6M	/qcls-vs-cdio →
BMRA Biomerica Inc.	D-	39/100	—	8.1%	-35.0%	-0.57%	$8.0M	/bmra-vs-cdio →
VRAX Virax Biolabs Group Limited	D+	58/100	—	—	—	+10.00%	$1.8M	/vrax-vs-cdio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001870144

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cardio Diagnostics Holdings Inc. (CDIO) reported GAAP revenue of $14.8K (-57.5% vs. FY2024 revenue of $34.9K , and -13.1% cumulative change since FY2023) , GAAP net income of -$6.5M, operating cash flow of -$5.7M, and free cash flow of -$5.9M (-13.6% YoY). On the balance sheet, CDIO closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$14.8K	-$6.5M	-$5.7M	-$5.9M	$7.8M	—
FY2024 (FY)	2024-12-31	$34.9K	-$8.4M	-$5.0M	-$5.2M	$10.6M	—
FY2023 (FY)	2023-12-31	$17.1K	-$8.4M	-$5.7M	-$5.7M	—	—

3. CDIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CDIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.75 (+2.94% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CDIO ranks #937 in composite RQD confidence.

How does CDIO compare to TRIB and QCLS in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), CDIO carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TRIB (Trinity Biotech plc) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $5.4M) and QCLS (Q/C Technologies Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $3.6M). Among the 5-stock peer group, CDIO leads on earnings multiple (N/A) while CDIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CDIO?

Per CDIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001870144), Cardio Diagnostics Holdings Inc. generated $14.8K in revenue (-57.5% YoY), -$6.5M in net income, and -$5.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CDIO trading relative to its 50-day, 200-day, and 52-week technical levels?

CDIO last traded at $1.75 (+2.94% on volume of 5,717 shares), positioning the stock -6.42% below its 50-day simple moving average ($1.87) and -15.46% below its 200-day simple moving average ($2.07). Across its 52-week range of $0.97 to $7.91, CDIO sits at the 11.2% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).

CDIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CDIO pay a dividend and is it safe?

Cardio Diagnostics Holdings Inc. (CDIO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CDIO RQD Cockpit CDIO 12M Forecast CDIO Earnings & Move CDIO Dividends & DRIP CDIO Insiders & 13F CDIO Whale Options CDIO Profit Sankey CDIO News & Why